Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-07
2011-12-20
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000
Reexamination Certificate
active
08080553
ABSTRACT:
The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3934036 (1976-01-01), Irikura
patent: 3944577 (1976-03-01), Laurent et al.
patent: 4034087 (1977-07-01), Voorhees
patent: 4107306 (1978-08-01), Voorhees
patent: 4254122 (1981-03-01), Brown
patent: 4367217 (1983-01-01), Gruber et al.
patent: 4499093 (1985-02-01), Galabov et al.
patent: 4554271 (1985-11-01), Braughler et al.
patent: 4685911 (1987-08-01), Konno et al.
patent: 4879119 (1989-11-01), Konno et al.
patent: 5051262 (1991-09-01), Panoz et al.
patent: 5242921 (1993-09-01), Milstone et al.
patent: 5270047 (1993-12-01), Kauffman et al.
patent: 5314688 (1994-05-01), Kauffman et al.
patent: 5326764 (1994-07-01), Milstone et al.
patent: 5428040 (1995-06-01), Magolda et al.
patent: 5468729 (1995-11-01), Chretien et al.
patent: 5639759 (1997-06-01), Magolda et al.
patent: 5668116 (1997-09-01), Cullis-Hill et al.
patent: 5728712 (1998-03-01), Montana et al.
patent: 5756553 (1998-05-01), Iguchi et al.
patent: 5762918 (1998-06-01), Thorpe
patent: 5792476 (1998-08-01), Hallgren
patent: 5874437 (1999-02-01), Garvey et al.
patent: 5874441 (1999-02-01), Magolda et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 6010716 (2000-01-01), Saunal et al.
patent: 6015577 (2000-01-01), Eisert et al.
patent: 6054487 (2000-04-01), Sekut et al.
patent: 6071514 (2000-06-01), Grinnell et al.
patent: 6110910 (2000-08-01), Magolda et al.
patent: 6133272 (2000-10-01), Garvey et al.
patent: 6172060 (2001-01-01), Garvey et al.
patent: 6172068 (2001-01-01), Garvey et al.
patent: 6177428 (2001-01-01), Garvey et al.
patent: 6197778 (2001-03-01), Garvey et al.
patent: 6197782 (2001-03-01), Garvey et al.
patent: 6211179 (2001-04-01), Garvey et al.
patent: 6221881 (2001-04-01), Garvey et al.
patent: 6232321 (2001-05-01), Garvey et al.
patent: 6265427 (2001-07-01), Camden
patent: 6316457 (2001-11-01), Garvey et al.
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6337325 (2002-01-01), Schonharting et al.
patent: 6372254 (2002-04-01), Ting et al.
patent: 6383471 (2002-05-01), Chen et al.
patent: 6403571 (2002-06-01), Gould et al.
patent: 6462044 (2002-10-01), Garvey et al.
patent: 6515010 (2003-02-01), Franchini et al.
patent: 6602521 (2003-08-01), Ting et al.
patent: 6677326 (2004-01-01), Bardsley et al.
patent: 6730321 (2004-05-01), Ting et al.
patent: 7253155 (2007-08-01), Keith et al.
patent: 2001/0007083 (2001-07-01), Roorda et al.
patent: 2001/0016604 (2001-08-01), Yu et al.
patent: 2002/0019405 (2002-02-01), Garvey et al.
patent: 2003/0003151 (2003-01-01), Chopra
patent: 2003/0023087 (2003-01-01), Garvey et al.
patent: 2003/0069169 (2003-04-01), Macor et al.
patent: 2003/0077229 (2003-04-01), Dugger
patent: 2003/0078246 (2003-04-01), Sackeyfio et al.
patent: 2003/0203028 (2003-10-01), Ting et al.
patent: 2004/0087486 (2004-05-01), Hanson
patent: 2004/0087591 (2004-05-01), Garvey et al.
patent: 2004/0180812 (2004-09-01), Dicker et al.
patent: 2005/0019393 (2005-01-01), Augsburger et al.
patent: 2005/0025713 (2005-02-01), Dugger
patent: 2005/0037074 (2005-02-01), Ross et al.
patent: 2005/0058688 (2005-03-01), Boerger et al.
patent: 2005/0119160 (2005-06-01), Keith et al.
patent: 2006/0234991 (2006-10-01), Keith et al.
patent: 2007/0010502 (2007-01-01), Keith et al.
patent: 2007/0196491 (2007-08-01), Venkatesh
patent: 2007/0213296 (2007-09-01), Zhang
patent: 2007/0213308 (2007-09-01), Lessem et al.
patent: 2009/0075955 (2009-03-01), Padval
patent: 1246335 (2000-03-01), None
patent: 0 303 713 (1993-05-01), None
patent: 0 543 653 (1993-05-01), None
patent: 1 093 814 (2001-04-01), None
patent: 2 292 079 (1996-02-01), None
patent: WO 89/10122 (1989-11-01), None
patent: WO 92/16226 (1992-10-01), None
patent: WO 98/19672 (1998-05-01), None
patent: WO 98/55142 (1998-12-01), None
patent: WO 99/16417 (1999-04-01), None
patent: WO 99/62537 (1999-12-01), None
patent: WO 00/12076 (2000-03-01), None
patent: WO 00/12497 (2000-03-01), None
patent: WO 00/59475 (2000-10-01), None
patent: WO 01/47572 (2001-07-01), None
patent: WO 01/54679 (2001-08-01), None
patent: WO 01/68056 (2001-09-01), None
patent: WO 02/22127 (2002-03-01), None
patent: WO 02/069905 (2002-09-01), None
patent: WO 02/085304 (2002-10-01), None
patent: WO 02/094227 (2002-11-01), None
patent: WO 03/006026 (2003-01-01), None
patent: WO 03/030823 (2003-04-01), None
patent: WO 03/043603 (2003-05-01), None
patent: WO 2004/019909 (2004-03-01), None
patent: WO 2004/069254 (2004-08-01), None
patent: WO 2005/020933 (2005-03-01), None
patent: WO 2005/030132 (2005-04-01), None
patent: WO 2005/037203 (2005-04-01), None
patent: WO 2007/089617 (2007-08-01), None
patent: WO 2007/103373 (2007-09-01), None
Boileau et al. Arthritis & Rheumatism, 2002, vol. 46, No. 10, pp. 2637-2647.
Forrest C M et al., “Adenosine and Cytokine Levels Following Treatment of Rheumatoid Arthritis with Dipyridamole”,Rheumatology International. 27(1) 11-17 (2006).
Green, P G et al., “Purinergic Regulation of Bradykinin-Induced Plasma Extravasation and Adjuvant-Induced Arthritis in The Rat”,Proceedings of the National Academy of Sciences, 88:10; 4162-4165 (1991).
European Search Report for EP09002049 dated Mar. 18, 2009.
Afeltra, “Treatment of Rheumatoid Arthritis: New Therapeutic Approaches with Biological Agents,”Curr. Drug Targets Immune. Endocr. Metabol. Disord. 1:45-65 (2001).
Badger et al., “Disease-Modifying Activity of SB242235, A Selective Inhibitor of p38 Mitogen-Activated Protein Kinase, in Rat Adjuvant-Induced Arthritis,”Arthritis. Rheum. 43:175-183 (2000).
Barlow et al., “Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP),”Bioorg. &Med. Chem. Lett. 10:585-589 (2000).
Barnes, “Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms,”Clin. Sci. 94:557-572 (1998).
Baxter et al., “Mechanism of Glucocorticoid Action: General Features, with Reference to Steroid-Mediated Immunosuppression,”Transplant. Proc. 7:55-65 (1975).
Berger et al., “Comparative Carcinogenic Activity of Prednimustine, Chlorambucil, Prednisolone and Chlorambucil Plus Prednisolone in Sprague-Dawley Rats,”Arch. Geschwulstforsch55:429-442 (1985).
Berger et al., “Long-Term Toxicology Effects of Prednimustine in Comparison with Chlorambucil, Prednisolone, and Chlorambucil Plus Prednisolone in Sprague-Dawley Rats,”Semin. Oncol. 13:8-13 (1986).
Berkow et al., “The Merck Manual,” fifteenth edition, pp. 797-807 (1987).
Berkow et al., “Merck Manual of Medical Information,” Home edition, pp. 248-255 (1997).
Brunette et al., “Long-term Immunosuppressive Treatment of a Child with Takayasu's Arteritis and High IgE Immunoglobulins,”Pediatr. Nephrol. 10:67-69 (1996).
Bruserud, “Dipyridamol Inhibits Activation of Human T Lymphocytes In Vitro,”Clin. Immunol. Immunopathol. 42:102-109 (1987).
Cass et al., “A Comparison of the Abilities of Nitrobenzylthioinosine, Dilazep, and Dipyridamole to Protect Human Hematopoietic Cells From 7-Deazaadenosine (Tubercidin),”Cancer Res. 52:5879-5886 (1992).
Cazenave et al., “Inhibition of Platelet Adherence to a Collagen-coated Surface by Nonsteroidal Anti-inflammatory Drugs, Pyrimido-pyrimidine and Tricyclic Compounds, and Lidocaine”J. Lab. Clin. Med. 83:797-806 (1974).
Conway et al., “Inhibition of Cartilage and Bone Destruction in Adjuvant Arthritis in the Rat by a Matrix Metalloproteinase Inhibitor,”J. Exp. Med. 182:449-457 (1995).
Curtin et al., “
Auspitz Benjamin A.
Borisy Alexis
Foley Michael A.
Hurst Nicole
Jost-Price Edward Roydon
Clark & Elbing LLP
Jean-Louis Samira
Padmanabhan Sreeni
Zalicus Inc.
LandOfFree
Methods and reagents for the treatment of immunoinflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for the treatment of immunoinflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for the treatment of immunoinflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4304455